Robust Sofinnova exit gives Ablynx chance of strategic independence
This article was originally published in Scrip
The last major venture investor in Ablynx found institutional buyers on 18 November for the last of its shares in the company, and with that the Belgian mini-antibody developer completed a significant right of passage: it is now owned by accumulators rather than speculators. That, according to CEO Edwin Moses gives Ablynx' board the chance to make longer-term strategic plans for the business without the distraction of early investors' exit anxieties.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.